Methodology for Clinical Trials Involving Patients with Cancer Who Have Febrile Neutropenia: Updated Guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with Emphasis on Outpatient Studies
Open Access
- 15 December 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12), 1463-1468
- https://doi.org/10.1086/344650
Abstract
Two multinational organizations, the Immunocompromised Host Society and the Multinational Association for Supportive Care in Cancer, have produced for investigators and regulatory bodies a set of guidelines on methodology for clinical trials involving patients with febrile neutropenia. The guidelines suggest that response (i.e., success of initial empirical antibiotic therapy without any modification) be determined at 72 h and again on day 5, and the reasons for modification should be stated. Blinding and stratification are to be encouraged, as should statistical consideration of trials specifically designed for showing equivalence. Patients enrolled in outpatient studies should be selected by use of a validated risk model, and patients should be carefully monitored after discharge from the hospital. Response and safety parameters should be recorded along with readmission rates. If studies use these guidelines, comparisons between studies will be simpler and will lead to further improvements in patient therapy.Keywords
This publication has 17 references indexed in Scilit:
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer ChemotherapyThe New England Journal of Medicine, 1999
- Fever and Neutropenia — How to Use a New Treatment StrategyThe New England Journal of Medicine, 1999
- A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer ChemotherapyThe New England Journal of Medicine, 1999
- Methodology for clinical trials in cancer patients with febrile neutropeniaSupportive Care in Cancer, 1998
- An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patientsEuropean Journal of Cancer, 1995
- Evaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic PatientsClinical Infectious Diseases, 1992
- From the Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient: Report of a Consensus PanelThe Journal of Infectious Diseases, 1990
- Reporting the results of randomized trials of empiric antibiotics in febrile neutropenic patients--a critical survey.Journal of Clinical Oncology, 1986
- A method for assessing the quality of a randomized control trialControlled Clinical Trials, 1981